What does Insulet do and what are its main business segments?

What were the key takeaways from Insulet’s earnings call?

What were the key takeaways from Insulet's earnings call?

What is the market's earnings forecast for Insulet next quarter?

What is the revenue and EPS growth rate for Insulet year over year?

What factors drove the changes in Insulet's revenue and profit?

Did Insulet beat or miss consensus estimates last quarter?

What is Insulet's latest dividend and current dividend yield?

- **Revenue Growth**: Q4 2025 revenue up 31.2% YoY to $784 million; full-year $2.7 billion (+30.7% YoY). U.S. type 2 diabetes adoption drove 40% of new starts.
- **Margin Expansion**: Gross margin 72.5% (Q4), operating margin 17.6% (full-year, +270bps YoY). Free cash flow $375 million (+24% YoY).
- **Pipeline Innovations**: Omnipod 6 launch in 2027 with 100-step algorithm; fully closed-loop system for type 2 in 2028. DexCom G7 and Libre 3 integrations enhance CGM compatibility.
- **Market Leadership**: 30,000+ prescribers, 70% brand request rate, and highest NPS in AID category. 2026 guidance: 20-22% revenue growth, 100bps margin expansion.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q4 2025 revenue of $784 million, up 31.2% YoY (29% constant currency). Full-year revenue reached $2.7 billion, growing 30.7% YoY (29.5% constant currency). U.S. revenue grew 28% YoY, driven by Omnipod 5 adoption in type 1 and type 2 diabetes. International revenue surged 44.1% YoY (39.3% constant currency) due to Omnipod 5 launches in 9 new markets.
- **New Customer Starts**: Q4 saw record new customer starts in both U.S. and international markets, with type 2 representing 40% of U.S. starts. Global utilization and retention rates remained stable.
- **Pipeline Innovations**: Launch of Omnipod 6 with 100-step target algorithm, real-time software updates, and compatibility with all CGM systems. Fully closed-loop system for type 2 diabetes expected to launch in 2028, targeting 5.5 million insulin-dependent patients with unmet needs.
- **Margin Expansion**: Gross margin improved to 72.5% in Q4 (71.6% full-year), up 180 basis points YoY. Operating margin expanded 270 basis points to 17.6%.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q4 non-GAAP EPS of $1.55, up 35% YoY. Full-year EPS of $4.97, up 53% YoY. Free cash flow of $375 million (including $70 million tax benefit), up 24% YoY. Share buybacks of $59.6 million in 2025.
- **2026 Guidance**: Total revenue growth of 20-22% (U.S.: 20-22%, International: 24-26%). Operating margin expected to expand 100 basis points. Capital expenditures of $135 million in Q4, supporting Malaysia and Costa Rica manufacturing expansions.
- **Leverage and Efficiency**: Malaysia facility became margin-accretive within 1 year of launch. AI-driven customer service improvements reduced cost-to-serve while enhancing retention.

**【Q&A Highlights】**
- **Competition and Market Penetration**: CEO Ashley McEvoy emphasized Insulet's 25-year tech lead, $3 billion R&D investment, and 30,000+ prescriber network as competitive moats. Type 2 diabetes penetration at 5% vs. 40% in type 1, with 5.5 million insulin-dependent patients underserved. Omnipod 5's 70% brand request rate and highest Net Promoter Score reinforce leadership.
- **Sensor Integration**: Omnipod 5 compatible with DexCom G7 (15-day sensor) and FreeStyle Libre 3. Omnipod 6 will feature over-the-air updates for faster innovation cycles.
- **Clinical Evidence**: Omnipod 5 shown to reduce A1c more effectively than competitors in independent studies. Fully closed-loop system designed for primary care simplicity: no dosing, mealtime actions, or clinician-defined settings.
- **Financial Flexibility**: $760 million cash balance and $500 million credit facility support $350 million share buyback authorization for 2026.

Insulet Corporation(PODD)-20260218-2025 Q4 Earnings call transcript

- **Record Growth**: Q3 revenue surpasses $700M, up 28% YoY, with Omnipod 5 driving U.S. and international expansion.
- **Market Leadership**: U.S. Type 1 new starts at highest level in 2 years; Type 2 new starts double YoY, 35% of U.S. new starts.
- **Financial Strength**: Gross margin 72.2%, operating margin 17.1%, with full-year guidance raised to 29-30% revenue growth.
- **Strategic Momentum**: $30M share buybacks, $760M cash, and accelerated R&D for next-gen products like hybrid closed-loop.
- **Type 2 Adoption**: DTC campaigns generate 65% of leads from new prescribers, Type 2 prescriber base up 26% QoQ.

**【CEO Summary Section】**
- **Revenue Milestone**: Q3 revenue exceeded $700 million, a 28% year-over-year (YoY) growth at constant currency, driven by Omnipod 5 adoption across U.S. Type 1, Type 2, and international markets.
- **Market Leadership**: U.S. Type 1 new customer starts grew sequentially and YoY, with competitive conversions at the highest level since late 2023. Type 2 new starts doubled YoY, reflecting strong DTC demand and prescriber expansion.
- **International Expansion**: International revenue grew 40% YoY (constant currency), led by Omnipod 5 launches in Germany, U.K., France, and Canada. Global utilization and retention rates remained stable.
- **Strategic Investments**: Accelerated R&D (41% YoY increase) for next-gen products like hybrid closed-loop and fully closed-loop systems. Manufacturing scale-up and AI-driven service optimization support growth.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP revenue $700M+, 28% YoY growth. Gross margin 72.2%, up 290bps YoY. Adjusted EBITDA margin 22.7%, operating margin 17.1%.
- **Guidance Update**: Full-year 2025 Omnipod revenue growth raised to 29-30% (prev. 25-28%). U.S. Omnipod growth 26-27% (prev. 22-25%). International growth 38-39% (prev. 34-37%).
- **Cash Flow & Capital Allocation**: $760M cash on hand. $30M share buybacks to offset dilution. Capital expenditures to accelerate manufacturing expansion.
- **Tax & Expense Management**: Non-GAAP tax rate 22-23%. Net interest expense up $20M YoY due to debt transition.

**【Q&A Key Highlights】**
- **Competitive Positioning**: Omnipod 5 winning on form factor, algorithm, and ease of onboarding. 85% of U.S. new starts from MDI, 35% from Type 2. Competitive conversions highest in 2 years.
- **Type 2 Adoption**: DTC campaigns generated 65% of leads from prescribers not previously called on. Type 2 prescriber base grew 26% QoQ, NCS up 100% YoY.
- **Guidance Philosophy**: Balanced outlook with confidence in achieving targets while acknowledging risks. 2026 guidance to be provided post-Investor Day.
- **International Momentum**: Canada and Australia Omnipod 5 launches driving share. Germany G7 uptake rapid. 2026 rollouts planned for additional markets.
- **Supply Chain Resilience**: $1B+ invested in manufacturing scale. 55% U.S. users now on phone control, improving retention and outcomes.

Insulet Corporation (PODD) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue $649 million (+31% YoY), driven by 38.8% international growth and 28.7% U.S. expansion.
- **Margin Expansion**: Adjusted operating margin 17.8%, up 150bps YoY, with full-year guidance of 17-17.5%.
- **Type 2 Breakthrough**: 30% of U.S. new starts from Type 2, with 0.8% A1c reduction in clinical trials.
- **International Dominance**: 40% YoY growth in key markets, 50% Omnipod 5 adoption, and 34-37% full-year international growth.
- **Strategic Investments**: $12 million interest savings from debt refinancing and accelerated CapEx for manufacturing scale.

**【CEO Summary Section】**
- **Record Q2 Performance**: Revenue reached $649 million, up 31% YoY, surpassing $600 million for the first time. New customer starts grew year-over-year and sequentially across U.S. Type 1, U.S. Type 2, and international markets.
- **Omnipod 5 Success**: Driven by strong clinical outcomes (0.8% A1c reduction in SECURE-T2D trial), Omnipod 5 adoption accelerated, with 25,000+ prescribers in the U.S. and 500,000+ Podders globally.
- **Strategic Priorities**: 
  1. **Commercial Expansion**: Scaling U.S. sales team and penetrating international markets (U.K., France, Germany) with 40% YoY growth.
  2. **Innovation**: Advancing hybrid closed-loop and fully closed-loop algorithms, with G7 iOS app integration boosting app adoption (55% eligible U.S. Podders still use controllers).
  3. **Global Scale**: Investing in manufacturing (Malaysia plant expansion) and market development to meet demand.

**【CFO Financial Commentary】**
- **Revenue Growth**: Total revenue $649 million (+31% YoY). U.S. Omnipod up 28.7%, international up 38.8% (620bps FX tailwind). Full-year guidance raised to 25-28% growth.
- **Profitability**: Adjusted operating margin 17.8% (vs. 16.3% prior year), driven by $10 million inventory write-offs and 70.7% gross margin (year-to-date). Full-year gross margin guidance reaffirmed at ~71%.
- **Cash Flow**: $1.1 billion cash on hand, $30 million share buybacks, and $12 million interest savings from term loan refinancing.
- **Guidance Updates**: 
  - Q3 revenue: 24-27% growth (22-25% U.S., 33-36% international). 
  - Full-year adjusted operating margin: 17-17.5% (vs. 16.3% prior year).

**【Q&A Highlights】**
- **Type 2 Momentum**: 30% of U.S. new starts from Type 2, driven by clinical evidence (20% improvement in time in range vs. MDI) and 47,000 pharmacy access points at $1/day.
- **International Growth**: 38.8% YoY growth, 50% Omnipod 5 adoption in key markets, and 34-37% full-year guidance for international revenue.
- **CapEx Acceleration**: Investing in supply chain to meet demand, including new manufacturing lines in Acton and Malaysia.
- **Competitive Switches**: Highest quarter of competitive switches since Q4 2023, reflecting Omnipod 5's simplicity and clinical advantage.


Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: 30% revenue increase to $569M, Omnipod U.S. +26%, International +36%.
- **Profitability Expansion**: 71.9% gross margin (up 240bps), 16.4% operating margin (160bps YoY expansion).
- **Type 2 Market Dominance**: 30%+ of U.S. new starts in type 2, HCP engagement up 20% YoY.
- **Global Ambition**: 13 international markets launched with Omnipod 5, targeting 20-23% annual growth.
- **Financial Strength**: $1.3B cash, 71%+ gross margin target, $125M share buyback program.

**【CEO Opening Remarks】**
- New CEO Ashley McEvoy emphasizes Insulet's unique position at the intersection of consumer health and MedTech, with a focus on innovation and scaling. 
- Q1 2025 revenue grew 30% YoY to $569M, driven by 29% Omnipod growth, with 30%+ of U.S. new customer starts in type 2 diabetes.
- Strategic priorities include expanding U.S. type 1/type 2 market share, accelerating international growth (13 markets launched with Omnipod 5), and leveraging data for direct-to-consumer engagement.

**【CFO Financial Highlights】**
- Q1 2025 GAAP revenue: $569M (+30% YoY), Omnipod U.S. +26%, International +36%.
- Gross margin: 71.9% (up 240bps YoY), driven by manufacturing efficiency and scale.
- Operating margin: 16.4%, with 160bps YoY expansion through cost control.
- Full year 2025 guidance: Omnipod revenue +20-23%, gross margin 71%, free cash flow growth.
- Tariffs: 50bps impact expected, offset by operational efficiency.

**【Q&A Key Takeaways】**
- **Type 2 Expansion**: 30%+ of U.S. new starts in Q1, HCP engagement up 20% YoY, DTC conversion rates improving.
- **International Growth**: Middle East launches Q4 2025-Q1 2026, 3.5M addressable type 1 patients globally (20-25% penetration).
- **Margins**: 71%+ gross margin target for 2025, 100+bps annual operating margin expansion.
- **Supply Chain**: $1B+ invested in automation, 3 global manufacturing sites (U.S., China, Malaysia) ensure resilience.
- **Debt Optimization**: $450M bond issuance to refinance convertible notes, reducing cost of capital.


Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript

- **Revenue Doubling**: 2024 revenue reached $2.1B, doubling in 3 years, with 22% growth driven by Omnipod 5 adoption.
- **500K Customers**: 365K active Omnipod 5 users highlight recurring revenue strength and 90%+ U.S. market penetration.
- **Type 2 Leadership**: 30%+ type 2 new starts in Q4, targeting 40%+ mix with first-to-market label and DTC growth.
- **Intl Expansion**: 2025 launches in 5+ markets, G7 sensor integrations, and 22-26% intl revenue growth.
- **Margin Targets**: 70.5% gross margin, 16.5% operating margin, supported by pharmacy scale and R&D investment.

**【CEO Summary Section】**
- **Revenue Milestone**: Achieved $2.1 billion in 2024, doubling from $1 billion in 2021, with 22% constant currency growth. 500,000 global customers, including 365,000 active Omnipod 5 users.
- **Omnipod 5 Expansion**: 90%+ U.S. adoption in Q4, 30%+ type 2 new customer starts, and rapid international rollout to 5 new European markets.
- **Innovation**: Launched Omnipod Discover, a digital health platform for clinician-patient data sharing, and integrated with Abbott Libre 2 Plus and Dexcom G7 sensors.
- **Market Leadership**: 24,000+ HCPs prescribing Omnipod 5, with 85% U.S. new starts from MDI switchers.

**【CFO Financial Commentary】**
- **2024 Financials**: GAAP revenue $2.1B (22% growth), gross margin 69.8%, operating margin 14.9%, free cash flow $305M.
- **2025 Guidance**: Total revenue 16-20% growth, U.S. Omnipod 16-20%, International 22-26%. Gross margin 70.5%, operating margin 16.5%.
- **Key Drivers**: U.S. pharmacy channel scale, international sensor integrations, R&D investment in closed-loop algorithms.

**【Q&A Highlights】**
- **Type 2 Growth**: 30%+ new customer starts in Q4, targeting 40%+ mix by leveraging first-to-market label and DTC engagement.
- **International Momentum**: France/Netherlands adoption strong, 5 new market launches in 2025, G7 sensor rollouts in U.K./Netherlands.
- **Margin Strategy**: 70.5% gross margin target reflects scale benefits, offset by lower-margin intl growth. Operating margin expansion via R&D and sales force expansion.
- **Competitive Edge**: Pharmacy channel dominance (95% PBM coverage), unique form factor, and data-driven algorithms.

Actual											-0.03	0.22	0.17	-0.26	0	-0.37	0.18	0.42	0.4	-0.5	-0.08	0.24	0.34	0.39	0.74	1.44	0.73	0.55	0.9	1.15	1.02	1.17	1.24	1.55
Forecast											-0.0055	0.0021	0.0784	-0.0399	0.0725	0.1347	0.248	0.3136	0.232	0.2246	0.1521	0.2193	0.1063	0.2625	0.403	0.653	0.4012	0.5637	0.7777	1.0036	0.79	0.9198	1.1402	1.4617
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-445.45%	+10376.19%	+116.84%	-551.63%	-100.00%	-374.68%	-27.42%	+33.93%	+72.41%	-322.62%	-152.60%	+9.44%	+219.85%	+48.57%	+83.62%	+120.52%	+81.95%	-2.43%	+15.73%	+14.59%	+29.11%	+27.20%	+8.75%	+6.04%

PODD

PODD fundamentals

PODD Q4 2025 Earnings

Earnings Call

You can ask Aime

PODD

PODD fundamentals

PODD Q4 2025 Earnings

Earnings Call

PODD Earnings Call Summary for Q4/20258:00 AM on Feb 18, 2026

PODD Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

PODD Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

PODD Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

PODD Earnings Call Summary for Q4/20244:30 PM on Feb 20, 2025

You can ask Aime